{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-064145","form_type":"8-K","ticker":"SVRA","cik":"0001160308","company_name":"Savara Inc","filed_at":"2025-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.056490+00:00","generated_at":"2026-05-24T04:45:18.838570+00:00","sec_items":["1.01","1.02","2.03","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Savara secures up to $200M non-dilutive debt from Hercules Capital, $30M drawn at close","bullets":["$30M initial draw used to repay existing $26.5M SVB debt; up to $170M additional available contingent on FDA approval of MOLBREEVI and other milestones.","Interest-only period of 36 months (extendable to 60 months upon FDA approval); floating rate of prime+1.45% (floor 6%+1.45%).","No warrants issued; loan matures April 1, 2030; collateral includes tangible assets (negative pledge on IP).","Milestone triggers: $80M available upon FDA approval (by end of 2025 if priority review), $20M upon revenue milestone post-2027, $70M at Hercules discretion."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-064145","json":"https://secwatch.observer/filing/0001193125-25-064145.json","markdown":"https://secwatch.observer/filing/0001193125-25-064145.md","text":"https://secwatch.observer/filing/0001193125-25-064145.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1160308/000119312525064145/0001193125-25-064145-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1160308/000119312525064145/d936539d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T04:45:18.838570+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}